Its companies stocked up ahead of the lockdown, and the group also says it has chronic medication stocks to last until the end of May
J&J shares rise 7% after it announces a $1bn deal with the US government to create enough manufacturing capacity to make more than 1-billion doses of a vaccine
The medical-device maker plans to supply 50,000 tests a day starting April 1
Private hospital group withdraws its full-year guidance amid uncertainty over Covid-19 outbreak
The pharmaceutical manufacturer urges people not to hoard cold and flu medications, saying its supply chain is robust
Operating profit increases, with the group boosted by its acquisition of pharmaceutical group Activo Health during the period
The group is seeking to save money by limiting staff numbers and travel, as its debt far exceeds its market capitalisation
Netcare Group CEO Richard Friedland talks to Business Day TV about the coronavirus outbreak
Aspen CEO Stephen Saad talks to Business Day TV about the company’s interim results
Africa’s largest pharma company is upbeat over progress in cutting debt
Africa’s biggest drugmaker has over the past year been disposing of noncore assets to manage its debt
The day clinic operator says its offering remains competitive when compared to overnight hospitals
Adcock CEO Andy Hall talks to Business Day TV about the company’s performance
Discovery CEO Adrian Gore talks to Business Day TV about the group’s half-year performance
The government AIDS drug orders from the pharmaceutical company have been less than a third of those anticipated
Low interest rates in the UK have hit the group’s Vitality Life business
The group managed to grow profit in its half-year to end-December despite rising costs
The pharmacy group says that group revenue is up 10% in the 22 weeks to February 2, as it kept prices low and focused on promotions
Normalised profit at VitalityLife, which provides insurance to the UK market, is expected to fall 145% in the six months to end-December
Regulator opens door for patients to force schemes to fund treatments unavailable in state sector
